These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 20346244)

  • 1. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K; Zintzaras E; Tzioufas AG
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
    Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
    J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy].
    Liu G; Chen Y; Wang L; Zuo C; Xie Q; Wang Z; Lin M
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):294-5, 306. PubMed ID: 12600113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia.
    Alarfaj AS; Khalil N
    Clin Rheumatol; 2014 Dec; 33(12):1731-6. PubMed ID: 24894105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
    Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
    Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.
    Boumpas DT; Austin HA; Vaughan EM; Yarboro CH; Klippel JH; Balow JE
    Ann Intern Med; 1993 Sep; 119(5):366-9. PubMed ID: 8338289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand.
    Akawatcharangura P; Taechakraichana N; Osiri M
    Lupus; 2016 Apr; 25(4):436-44. PubMed ID: 26621134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study.
    Sharma SK; Jain S; Bahl P; Potturi P; Rathi M; Naidu S; Sachdeva N; Dhir V; Jain S
    Arthritis Res Ther; 2020 Aug; 22(1):189. PubMed ID: 32799907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
    Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
    Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide.
    Katsifis GE; Tzioufas AG
    Lupus; 2004; 13(9):673-8. PubMed ID: 15485101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
    Rivera TL; Belmont HM; Malani S; Latorre M; Benton L; Weisstuch J; Barisoni L; Tseng CE; Izmirly PM; Buyon JP; Askanase AD
    J Rheumatol; 2009 Feb; 36(2):298-305. PubMed ID: 19040310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
    BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapies for proliferative lupus nephritis.
    Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
    N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.